2021 China New Design 2-(2-Methyl-5-nitroanilino)-4-(3-pyridyl)pyrimidine - 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4 Linagliptin Intermediate Purity ≥99.0% (HPLC) Factory – Ruifu

Manufacturer Supply, High Purity, Commercial Production Chemical Name: 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS: 666816-98-4 Intermediate for Linagliptin (CAS: 668270-12-0)

Chemical Name	8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine
Synonyms	8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1H-purine-2,6-dione; Linagliptin Intermediate C
CAS Number	666816-98-4
CAT Number	RF-PI497
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C10H9BrN4O2
Molecular Weight	297.11
Melting Point	285℃
Brand	Ruifu Chemical

Item	Specifications
Appearance	White to Off-White Powder
Water (K.F)	≤0.50%
Residue on Ignition	≤0.50%
Purity/Analysis Method	≥99.0% (HPLC)
Max Single Impurity	≤0.50%
Residual Solvents
Ethanol	≤5000ppm
DMF	≤3000ppm
Test Standard	Enterprise Standard
Usage	Intermediate for Linagliptin (CAS: 668270-12-0)

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture. 8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine (CAS: 666816-98-4) is an intermediate for Linagliptin (CAS: 668270-12-0). Linagliptin is an oral, highly selective inhibitor of dipeptidyl peptidase-4 and is the first agent of its class to be eliminated predominantly via a nonrenal route. Linagliptin is indicated for once daily use for the treatment of adults with type 2 diabetes mellitus. Linagliptin was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise.